Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

½Äµµ¾ÏÀÇ ¹æ»ç¼±Ä¡·á ¼ºÀû Treatment Results of Esophageal Carcinoma Treated

´ëÇѹæ»ç¼±Á¾¾çÇÐȸÁö 2000³â 18±Ç 3È£ p.182 ~ 186
¼Ò¼Ó »ó¼¼Á¤º¸
±è¹Ì¼÷/Mi Sook Kim ·ù¼º·Ä/Á¶Ã¶±¸/À¯ÇüÁØ/¾ç±¤¸ð/°­Áø¿À/Áö¿µÈÆ/À̵¿ÇÑ/·ù¹é·Ä*/Seoung Yul Yoo/Chul Koo Cho/Hyung Jun Yoo/Kwang Mo Yang/Jin Oh Kang/Young Hoon Ji/Dong Han Lee/Baek Yeol Ryoo*

Abstract

¸ñ Àû :¼ö¼úÀ» ½ÃÇàÇÏÁö ¾ÊÀº ½Äµµ¾Ï ȯÀÚ¿¡¼­ ¹æ»ç¼±Ä¡·á ÈÄ »ýÁ¸À² ¹× ¿¹ÈÄ ÀÎÀÚ¸¦ ÆľÇÇÏ¿© ÇâÈÄ Ä¡·á ¹æħ °áÁ¤¿¡ µµ¿òÀÌ µÇ°íÀÚ ÇÑ´Ù .
´ë»ó ¹× ¹æ¹ý :1992 ³âºÎÅÍ 1996 ³â±îÁö ¿øÀڷº´¿ø ¹æ»ç¼±Á¾¾çÇаú¿¡¼­ ±ÙÄ¡Àû ¶Ç´Â °í½ÄÀû ¸ñÀûÀ¸·Î Ä¡·á¸¦ ¹ÞÀº ½Äµµ¾Ï ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿© ÈÄÇâÀû ºÐ¼®À» ½ÃÇà ÇÏ¿´´Ù . ¼ö¼ú ¶Ç´Â ¹æ»ç¼±Ä¡·á ÈÄ Àç¹ßÇÑ È¯ÀÚ ¹× ¹æ»ç¼±Á¶»ç¸¦ 40 Gy ¹Ì¸¸À¸·Î ¹ÞÀº ȯÀÚ¸¦
Á¦¿ÜÇÑ 40
¸íÀÇ È¯ÀÚ¸¦ ´ë»óÀ¸·Î ÇÏ¿´´Ù . ÀÌ Áß ³²ÀÚ´Â 35 ¸í , ¿©ÀÚ´Â 5 ¸íÀ̾ú´Ù . 2 ¸íÀÇ È¯ÀÚ´Â »ý°ËÀ» ½ÃÇàÇÏÁö ¾Ê¾Ò°í ±× ¿Ü ȯÀÚ´Â ¸ðµÎ ÆíÆò
»óÇǾÏÀ̾ú´Ù . AJCC 1997 º´±âº° ºÐÆ÷´Â I 1 ¸í , ¥±A 6 ¸í , ¥±B 6 ¸í , ¥² 10 ¸í , ¥³A 12 ¸í , ¥³B 4 ¸í ÀÌ°í º´±â¸¦ ¾Ë ¼ö ¾ø´Â °æ¿ì°¡ 1 ¸íÀ̾ú´Ù . º¸Á¶ Ç×¾ÏÈ­Çпä¹ýÀ» ½ÃÇàÇÑ È¯ÀÚ´Â ¸ðµÎ 10 ¸íÀ̾ú´Ù .
Á¶»ç¼±·®ÀÇ ¹üÀ§´Â 40 ¡­60 Gy ÀÌ°í Áß¾Ó¼±·®Àº 59.4 Gy ¿´´Ù.
°á °ú :Àüü ȯÀÚÀÇ Áß¾Ó»ýÁ¸±â°£Àº 6.5 °³¿ùÀÌ°í 1 ³â »ýÁ¸À²Àº 28.3%ÀÌ´Ù . ¿¬·É ¹× º´º¯À§Ä¡ , ¹æ»ç¼±·® , Ç×¾ÏÈ­Çпä¹ý Ãß°¡¿¡ °üÇÑ »ýÁ¸À²ÀÇ Â÷ÀÌ´Â °üÂûµÇÁö ¾Ê¾Ò´Ù . °¢°¢ÀÇ º´±â¿¡ µû¶ó »ýÁ¸À²ÀÇ Â÷ÀÌ´Â
°üÂûµÇÁö ¾Ê¾Æ ÀÓ»óº´±â´Â ¿¹ÈÄ¿¡ Å« µµ¿òÀÌ µÇÁö ¾Ê¾Ò´Ù . ±×·¯³ª º´±â ¥²À̳»ÀÇ È¯ÀÚ¿Í º´±â ¥³ÀÌ»óÀÇ È¯ÀÚ »çÀÌ¿¡´Â Åë°èÇÐÀûÀ¸·Î ÀÇ¹Ì ÀÖÁö´Â ¾Ê¾ÒÁö¸¸ Áß¾Ó»ýÁ¸±â°£ÀÌ °¢°¢ 7.6 °³¿ù ¹× 6.2 °³¿ù·Î Â÷À̸¦ º¸¿´´Ù .
°á ·Ð :½Äµµ¾ÏÀÇ »ýÁ¸À²Àº ±ØÈ÷ ºÒ·®ÇÏ¿´´Ù. ȯÀÚÀÇ Àü½Å »óÅ µîÀ» °í·ÁÇÏ¿© ¿ÏÄ¡ ¹× °í½ÄÀû ¸ñÀûÀ» ±¸º°ÇÏ°í Ç×¾ÏÈ­Çпä¹ýÀÇ Ãß°¡ ¹× ½ºÅÙÆ® (stent), ¶Ç´Â ±ÙÁ¢ Á¶»çÄ¡·á¸¦ Ãß°¡ ÇÔÀ¸·Î »ýÁ¸À²ÀÇ Áõ°¡ ¹×
°í½ÄÀû Ä¡·á ¸ñÀûÀ» ´Þ¼ºÇÏ¿©¾ß ÇÒ °ÍÀÌ´Ù.

Purpose : To determine treatment protocol for inoperable esophageal cancer patients, we evaluated survival rate
and prognostic factors.
Materials and Methods : We evaluated esophageal cancer treated by curative or palliative aim in KCCH from
1992 to 1996, retrospectively. Recurrent or underdose case below 40 Gy were excluded. The number of male and
female were 35 and 5, respectively. Thirty-eight patients were squamous carcinoma and 2 patients were not
biopsy proven. Ten patients were treated with radiation therapy and chemotherapy. Median dose of radiation
therapy was 59.4 Gy and the range was 40 ¡­60 Gy.
Results : The median survival is 6.5 months and 1-year survival rate was 28.3%. Age, location, radiation dose and
chemotherapy were not significant prognostic factors. Median survivals of patients with below stage III and over
stage IVA were 7.6 and 6.2 months respectively, but it is not significant.
Conclusion : The survival for esophageal cancer is very poor. For patients with curative aim, chemotherapy must
be considered. For patients with palliative aim, short-term external beam radiation therapy and/or brachytherapy
must be considered.

Å°¿öµå

½Äµµ¾Ï; ¹æ»ç¼±Ä¡·á; »ýÁ¸À²; Esophageal cancer; Radiation therapy; Survival;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

   

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS